Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Qure.ai announced today that it appointed Jim Mercadante, a 25-year medtech veteran, as its new chief commercial officer (CCO ...

Mendaera announced today that it appointed surgical robotics veteran Eric Davidson as its first chief commercial officer (CCO ...

Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...

India's medical device industry, valued at US$12 billion, has become a growing hub for innovation, attracting venture capital ...

Onera Health, a leader in transforming sleep diagnostics and monitoring, is excited to announce the appointment of Maria ...

The FDA and European Medicines Agency (EMA) have granted several key designations to nipocalimab including: U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and ...

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...